SU 11248

Known as: SU 011248, SU011248, SU11248 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

sunitinibsunitinib malate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
PURPOSE Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and… (More)
  • table 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
PURPOSE There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those… (More)
  • figure 2
  • figure 1
  • figure 4
  • figure 3
  • figure 6
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.
UNLABELLED Liver cirrhosis is a very complex disease in which several pathological processes such as inflammation, fibrosis, and… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
PURPOSE Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
CONTEXT The oncogenic RET/PTC tyrosine kinase causes papillary thyroid cancer (PTC). The use of inhibitors specific for RET/PTC… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
PURPOSE A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Fifteen patients with refractory AML were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2003
Highly Cited
2003
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells. In… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic…
One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?